A favourable regulatory environment encouraged by the 21st Century Cures Act will help drive CRO demand for Medidata’s cloud-based technologies, according to a Citi analyst.
A Florida company is recalling 26 sexual enhancement and diet pills after the US FDA discovered some contain undeclared active pharmaceutical ingredients (APIs).
Midatech’s gold nanoparticle (GNP) drug conjugate technology and recent acquisitions are helping transfer the firm into a speciality pharma company, an analyst says.
Trial supplies of a radio-immunotherapy drug made by Areva Med in compliance with GMP are stable five years after they were produced according to the results of new analysis.
IBM Watson Health has struck deals with pharma company Teva and contract research organisation Icon to use its big data cloud tech to improve clinical trials and drug development.
Manufacturing backlog at Avid Bioservices has reached $42m as the firm books up space at a new facility currently undergoing its first internal pilot run.
Agilent Technologies has inked a deal to acquire Seahorse Bioscience, adding a cell metabolism analysis platform to its lead development and preclinical offerings.
Vladimir Putin says support from Russian business community is needed to help achieve the domestic drug manufacturing goals set out in his Pharma 2020 policy.
Sanofi’s decision to stop manufacturing an anti-venom will contribute to “needless death and disability” for snake bite victims, according to Médecins Sans Frontières.
Hospira’s injectables contracting business will operate alongside Pfizer’s CentreSource services unit following the completion of the $17bn takeover deal last week.
The EU needs to better define mercury limits for drugs and dietary supplements say Polish researchers who want pharmaceuticals in Europe to be tested more regularly.
AstraZeneca has licensed Starpharma’s Dendrimer Drug Delivery (DEP) platform to enhance the pharmaceutical properties in candidates in its oncology pipeline.
Investments in technologies and capabilities are reaping rewards says Catalent which will continue placing “disproportionate emphasis” on its biologics business.
Sandoz has joined biosimilar developers calling on the US FDA to provide clear guidance on interchangability just a day after launching Zarxio, its Neupogen (filgrastim) copycat.
An Indian TB drugmaker has been hit with a WHO Notice of Concern but an independent audit carried out by its customer Svizera Europe disputes the GMP violations raised.
GLP-1 drugs and oral formulations will not diminish demand for insulin patch-pumps says CeQur, which has raised $100m (€89m) to support production of its PaQ delivery device.
Sanofi wants to expand its inhalable drug production site in Cheshire, UK to increase capacity for both its own brand drug production operations and its contract manufacturing business.
Pfizer failed to report hundreds of serious adverse drug reactions (ADRs) in the required timeframes according to Japan’s Ministry of Health, Labor and Welfare (MHLW) which has issued the US firm with a business improvement order.
Boehringer Ingelheim has licensed a microbial expression technology from Vectron Biosolutions for use with its own molecules and for customers through its CMO business.
Amgen has retracted a study showing how grizzly bears could hold the key to understanding diabetes after one of the authors was found to have manipulated data.
The National Institute of Pharmaceutical Education and Research (NIPER) in India has created and licensed technology for producing nano-crystal based medicines that it says will cut drug costs.
Japanese industry group JPMA has opted for cloud-based tech to help it understand why the cost of running a trial in the country varies depending on the site involved.